Nebivolol Ipca (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. Additionally, it enhances nitric‑oxide release from the endothelium, causing vasodilation of peripheral vessels and further decreasing systemic vascular resistance.

The specific dose of Nebivolol Ipca is determined by the prescribing clinician based on the patient’s medical condition, age, renal function, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker that also promotes nitric‑oxide‑mediated vasodilation, which can result in better tolerability and fewer metabolic side effects compared with non‑selective beta blockers. This dual mechanism may offer advantages in patients who experience fatigue or cold extremities with other agents.

Nebivolol Ipca tablets should be stored at room temperature, below 25 °C, in the original blister or bottle. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Nebivolol Ipca is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not crush or split the tablet unless instructed.

Serious risks include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with asthma or COPD, and rare cases of hepatic dysfunction or allergic reactions. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic response.

Nebivolol Ipca is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure. Caution is also advised for patients with severe asthma or chronic obstructive pulmonary disease.